Literature DB >> 27698893

miR-143 is associated with proliferation and apoptosis involving ERK5 in HeLa cells.

Fang Zheng1, Jiahe Zhang2, Siyu Luo2, Jing Yi1, Ping Wang3, Quanqing Zheng2, Yurong Wen4.   

Abstract

Inappropriate expression of microRNA (miR) is strongly associated with carcinogenesis. miR-143 was reported to be one of the most prominent miRs implicated in the genesis and progression of human cancer. However, its correlation with cell proliferation and apoptosis in cervical cancer remains to be fully elucidated. In the present study, it was demonstrated that miR-143 is able to suppress the proliferation of cervical cancer HeLa cells and induce cell apoptosis in a time- and dose-dependent manner. The present study also investigated the potential targets of miR-143, extracellular-signal-regulated kinase 5 (ERK5) and its downstream substrate oncoprotein c-Fos, both of which are involved in cell proliferation and apoptosis. Upon increasing the miR-143 level, the ERK5 and c-Fos protein expression was significantly decreased without the effect of ERK5 transcription. Therefore, miR-143 is able to suppress cell proliferation and induce apoptosis in HeLa cells, potentially through negative regulation of ERK5 at its post-transcriptional stage.

Entities:  

Keywords:  HeLa cells; apoptosis; cervical cancer; extracellular-signal-regulated kinase 5; microRNA-143; proliferation

Year:  2016        PMID: 27698893      PMCID: PMC5038208          DOI: 10.3892/ol.2016.5016

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  42 in total

1.  ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins.

Authors:  Lixia Bai; Rui Mao; Jintao Wang; Ling Ding; Shiwen Jiang; Chenfei Gao; Huijie Kang; Xiao Chen; Xuesong Sun; Juan Xu
Journal:  Med Oncol       Date:  2015-02-03       Impact factor: 3.064

Review 2.  Functional significance of aberrantly expressed microRNAs in prostate cancer.

Authors:  Yusuke Goto; Akira Kurozumi; Hideki Enokida; Tomohiko Ichikawa; Naohiko Seki
Journal:  Int J Urol       Date:  2015-01-20       Impact factor: 3.369

3.  Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues.

Authors:  Heidi J Peltier; Gary J Latham
Journal:  RNA       Date:  2008-03-28       Impact factor: 4.942

Review 4.  Oncogenic microRNAs in the genesis of leukemia and lymphoma.

Authors:  Yanyan Pan; Mei Meng; Gaochuan Zhang; Hongyan Han; Quansheng Zhou
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  Forced expression of miR-143 represses ERK5/c-Myc and p68/p72 signaling in concert with miR-145 in gut tumors of Apc(Min) mice.

Authors:  Yuji Takaoka; Yuko Shimizu; Hitoki Hasegawa; Yasuo Ouchi; Shanlou Qiao; Miki Nagahara; Masatoshi Ichihara; Jiing-Dwan Lee; Koichi Adachi; Michinari Hamaguchi; Takashi Iwamoto
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

6.  Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth.

Authors:  Xiaohong Wang; Shuang Tang; Shu-Yun Le; Robert Lu; Janet S Rader; Craig Meyers; Zhi-Ming Zheng
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

7.  Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.

Authors:  Yao-Yin Chang; Wen-Hung Kuo; Jui-Hui Hung; Chien-Yueh Lee; Yung-Hua Lee; Ya-Chu Chang; Wen-Chun Lin; Cheng-Ying Shen; Chiun-Sheng Huang; Fon-Jou Hsieh; Liang-Chuan Lai; Mong-Hsun Tsai; King-Jen Chang; Eric Y Chuang
Journal:  Mol Cancer       Date:  2015-02-10       Impact factor: 27.401

Review 8.  Novel non invasive diagnostic strategies in bladder cancer.

Authors:  Anamaria Truta; Tudor Adrian Hodor Popon; George Saraci; Liviu Ghervan; Ioan Victor Pop
Journal:  Clujul Med       Date:  2016-04-15

Review 9.  MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers.

Authors:  Pannapa Pinweha; Khanti Rattanapornsompong; Varodom Charoensawan; Sarawut Jitrapakdee
Journal:  Comput Struct Biotechnol J       Date:  2016-06-04       Impact factor: 7.271

10.  miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.

Authors:  Cyrielle Clapé; Vanessa Fritz; Corinne Henriquet; Florence Apparailly; Pedro Luis Fernandez; François Iborra; Christophe Avancès; Martin Villalba; Stéphane Culine; Lluis Fajas
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

View more
  5 in total

1.  Long non-coding RNA HOTAIR promotes cervical cancer progression through regulating BCL2 via targeting miR-143-3p.

Authors:  Mingzhu Liu; Jinying Jia; Xinjie Wang; Yanjie Liu; Chunfang Wang; Ruitai Fan
Journal:  Cancer Biol Ther       Date:  2018-02-06       Impact factor: 4.742

2.  Restoration of miRNA-143 Expression Inhibits Growth and Migration of MKN-45 Gastric Cancer Cell Line.

Authors:  Nayer Hosseinahli; Tahereh Zeinali; Nasrin Hosseinahli; Leila Karimi; Dariush Shanehbandi; Behzad Mansoori; Ali Mohammadi; Tohid Kazemi; Khalil Hajiasgharzadeh; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2020-10-20

3.  Effect of Extracellular Signal-Regulated Protein Kinase 5 Inhibition in Clear Cell Renal Cell Carcinoma.

Authors:  Hidenori Kanno; Sei Naito; Yutaro Obara; Hiromi Ito; Osamu Ichiyanagi; Takafumi Narisawa; Tomoyuki Kato; Akira Nagaoka; Norihiko Tsuchiya
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

4.  MicroRNA‑1288 promotes cell proliferation of human glioblastoma cells by repressing ubiquitin carboxyl‑terminal hydrolase CYLD expression.

Authors:  Jun Yin; Chengyin Weng; Jieke Ma; Fanfan Chen; Yecai Huang; Mei Feng
Journal:  Mol Med Rep       Date:  2017-09-13       Impact factor: 2.952

5.  MicroRNA-217 functions as a tumor suppressor in cervical cancer cells through targeting Rho-associated protein kinase 1.

Authors:  Jing Dong; Maoxiu Wang; Donghua Ni; Lixin Zhang; Wen Wang; Xiujuan Cui; Shijie Fu; Shujuan Yao
Journal:  Oncol Lett       Date:  2018-08-20       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.